Similar articles

• The comparative safety/efficacy ratio of HFA-BDP.

  Lipworth BJ. Lipworth BJ. Respir Med. 2000 Sep;94 Suppl D:S21-6. doi: 10.1016/s0954-6111(00)90120-3. Respir Med. 2000. PMID: 11003171 Review.
• An overview of the clinical efficacy of HFA-BDP in asthma.

  Muir JF. Muir JF. Respir Med. 2000 Sep;94 Suppl D:S17-20. doi: 10.1016/s0954-6111(00)90119-7. Respir Med. 2000. PMID: 11003170 Review. No abstract available.
• Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.

  Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Chrousos GP, et al. Chest. 2005 Jul;128(1):70-7. doi: 10.1378/chest.128.1.70. Chest. 2005. PMID: 16002918 Clinical Trial.
• The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma.

  Fairfax AJ. Fairfax AJ. Respir Med. 2000 Sep;94 Suppl D:S31-6. doi: 10.1016/s0954-6111(00)90122-7. Respir Med. 2000. PMID: 11003173 Review. No abstract available.
• Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients.

  Ayres JG, Simmons JL, Stampone P. Ayres JG, et al. Respir Med. 1999 Jan;93(1):27-32. doi: 10.1016/s0954-6111(99)90073-2. Respir Med. 1999. PMID: 10464845 Clinical Trial.